Strs Ohio Has $46,000 Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Strs Ohio decreased its holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMPGet Rating) by 41.9% in the first quarter, HoldingsChannel reports. The institutional investor owned 5,400 shares of the biotechnology company’s stock after selling 3,900 shares during the period. Strs Ohio’s holdings in Oramed Pharmaceuticals were worth $46,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Renaissance Technologies LLC acquired a new position in Oramed Pharmaceuticals in the fourth quarter worth about $2,902,000. Allspring Global Investments Holdings LLC bought a new position in shares of Oramed Pharmaceuticals during the 4th quarter worth approximately $975,000. Qube Research & Technologies Ltd bought a new position in shares of Oramed Pharmaceuticals during the 4th quarter worth approximately $925,000. Swiss National Bank acquired a new stake in Oramed Pharmaceuticals in the 4th quarter valued at $920,000. Finally, OLD Mission Capital LLC bought a new stake in Oramed Pharmaceuticals in the fourth quarter valued at $553,000. 22.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 26th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Oramed Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $31.40.

Oramed Pharmaceuticals Price Performance

ORMP stock opened at $8.77 on Thursday. The business has a fifty day moving average price of $5.26 and a 200 day moving average price of $7.74. Oramed Pharmaceuticals Inc. has a fifty-two week low of $3.59 and a fifty-two week high of $31.54. The stock has a market capitalization of $338.17 million, a price-to-earnings ratio of -11.39 and a beta of 1.92.

Oramed Pharmaceuticals Company Profile

(Get Rating)

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.

See Also

Want to see what other hedge funds are holding ORMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oramed Pharmaceuticals Inc. (NASDAQ:ORMPGet Rating).

Institutional Ownership by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.